Application of D-limonene in preparation of medicine for treating pruritus
Through the atomization and inhalation method of D-limonene spray, it directly acts on the brain, solving the problems of many side effects and short-term efficacy of existing itching drugs, achieving rapid and continuous itching relief, and is safe and efficient.
Patent Information
- Application Number
- CN202411257885.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing drugs for treating pruritus have many side effects and short-term efficacy, which cannot meet patients' needs for rapid, effective and long-term treatment.
D-limonene is used as the main ingredient, and is administered through atomization and inhalation, combined with other drugs for treating pruritus, and is made into a nasal spray for treatment of acute and chronic itching, bypassing the blood-brain barrier and directly transported to the brain. Significant relief of symptoms.
D-limonene has no genes, immune and reproductive toxicity, has few side effects, can quickly and significantly relieve acute and chronic itching, and the effect lasts for three days, and is better than the external calamine lotion, and is safer.
Smart Images

Figure CN118903068A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug preparation for treating pruritus, and particularly relates to application of D-limonene in preparing drugs for treating pruritus. Background Art
[0002] Itching, or pruritus, is a symptom of abnormal skin sensation, mainly manifested as itching on the skin, which may be accompanied by a burning sensation, a tingling sensation, or a crawling sensation (such as the feeling of ants crawling on the skin). Itching can be systemic or localized, and often presents paroxysmal symptoms, and symptoms may be more severe at night. There are many causes of itching, including dryness, allergies, irritation, temperature changes, friction between clothing and bedding, etc. Survey results in the general population show that about 20% of people often experience itching, indicating that itching is a very common clinical symptom. In addition to skin symptoms, patients with pruritus also experience emotional disorders such as anxiety, irritability, insomnia, and inability to concentrate. About 10% of people said that antipruritic drugs need to be used for a long time, and they are inseparable from or dependent on them or cannot achieve satisfactory antipruritic effects. Therefore, it is very necessary to find a fast, effective, low-side-effect, and long-lasting treatment method.
[0003] At present, drugs for treating pruritus are mainly divided into two types: topical and systemic treatments, including antihistamines, glucocorticoids and glycyrrhizic acid preparations, bile acid-lowering drugs, immunosuppressants, antidepressants and anti-epileptic drugs, opioid μ receptor antagonists and opioid κ receptor agonists, leukotriene receptor antagonists, heparinoids, 5-hydroxytryptamine receptor antagonists, vitamin C and calcium gluconate, etc. However, these drugs for treating pruritus have the following problems: 1) There are side effects of varying degrees: such as central inhibition, local pain or paresthesia, drowsiness, obesity, gastrointestinal symptoms, peripheral neuropathy, etc. 2) There is a problem of short efficacy during the use of drugs.
[0004] D-limonene (limo), also known as limonene, is a monocyclic monoterpene with a molecular weight of 136.24 and a molecular formula of C 10 H 16 It is a lemon-flavored liquid that is insoluble in water and easily mixed with ethanol. It usually exists in the form of d-isomer with a pH value of about 6.7. In vivo studies have found that D-limonene has a chemopreventive effect in the initiation and promotion stages of various tumor systems (including breast cancer, skin cancer, liver cancer, lung cancer and forestomach cancer in rodents induced by chemical carcinogens). In addition, studies have found that a mixture containing 97% D-limonene can effectively dissolve cholesterol stones in patients with postoperative stones by administering it through gallbladder drainage. However, there are no reports that D-limonene can treat pruritus. Summary of the invention
[0005] In order to overcome the shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide an application of D-limonene in the preparation of a drug for treating pruritus, so as to solve the technical problems that the existing drugs for treating pruritus have many side effects and short efficacy.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The first aspect of the present invention discloses the use of D-limonene in preparing a medicine for treating pruritus.
[0008] Preferably, the pruritus is acute pruritus or chronic pruritus.
[0009] Further preferably, the acute pruritus is pruritus caused by histamine or non-histamine.
[0010] Preferably, the chronic pruritus is pruritus caused by atopic dermatitis.
[0011] Preferably, the chronic pruritus is pruritus caused by uremia.
[0012] Preferably, the dosage of D-limonene is (0.05-0.15) mL / kg.
[0013] Preferably, the drug is in the form of tablets, capsules, granules, syrups, premixes or pellets for oral administration, either alone or mixed with pharmaceutically acceptable excipients or diluents, or in the form of ointments, injections or sprays for non-oral administration.
[0014] Preferably, the spray is a nasal spray.
[0015] In a second aspect of the present invention, a nasal spray for treating pruritus is disclosed, comprising D-limonene.
[0016] Preferably, D-limonene and other drugs for treating pruritus are included.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] The application of D-limonene provided by the present invention in the preparation of a drug for treating pruritus is the first use of D-limonene for treating pruritus. On the one hand, atomized inhalation of D-limonene can activate the piriform cortex, and is dose-dependent; atomized inhalation of D-limonene can quickly and significantly relieve acute pruritus (histamine (His) itch, non-histamine itch) and chronic pruritus (atopic dermatitis, uremia-related pruritus), the drug effect can last for three days, and the effect is better than external calamine lotion; on the other hand, D-limonene has no gene, immune and reproductive toxicity, and is non-carcinogenic to other animals and humans, and has safety. Therefore, by giving D-limonene to treat pruritus, it is possible to solve the pain of pruritus patients on the basis of achieving clinical transformation, and has a good application prospect.
[0019] Furthermore, the administration method of atomized inhalation can bypass the blood-brain barrier and deliver D-limonene directly to the brain through the nasal cavity, which is beneficial to the rapid absorption and onset of D-limonene, has few side effects, and is convenient and non-invasive for patients to operate by themselves, which can improve patients' medication compliance. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The graphs are the results of the effects of different concentrations of D-limonene on c-fos by atomization inhalation of the present invention; wherein A is a DAB staining graph of c-fos protein at the piriform cortex, and B is a DAB staining counting result graph of c-fos protein at the piriform cortex;
[0021] Figure 2 This is a graph showing the results of a conditioned place preference experiment of mice after aerosol inhalation of D-limonene according to the present invention;
[0022] Figure 3 The graph is a result of the effect of D-limonene of the present invention on acute pruritus behavior; wherein A is the number of scratching times within 30 minutes after the injection of normal saline and histamine into the back of the neck of mice, and the injection of histamine after inhaling limonene, and the injection of histamine again 3 days after inhaling limonene; B is the number of scratching times within 30 minutes after the injection of normal saline and chloroquine (CQ) into the back of the neck of mice, and the injection of chloroquine after inhaling limonene, and the injection of chloroquine again 3 days after inhaling limonene;
[0023] Figure 4 The figures are the results of the effect of D-limonene of the present invention on chronic pruritus behavior; wherein A is the count of the number of scratching times within 30 minutes after 3 days in atopic dermatitis itch model mice inhaling limonene, B is the count of the number of scratching times within 30 minutes after 3 days in uremia-related pruritus model mice inhaling limonene, and C is the comparison of the antipruritic effects of D-limonene and calamine lotion. DETAILED DESCRIPTION
[0024] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.
[0025] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.
[0026] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values within the range (including integers and fractions).
[0027] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”
[0028] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.
[0029] The International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) have conducted a comprehensive evaluation of the safety and anti-cancer properties of D-limonene used in this article, indicating that D-limonene has no genetic, immune and reproductive toxicity, and is not carcinogenic to other animals and humans, and is safe.
[0030] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0031] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples are conventional commercial products unless otherwise specified, and their specifications are conventional specifications in the art. In the specification of the present invention and the following examples, unless otherwise specified, "%" represents volume percentage.
[0032] The D-limonene used in the following examples was purchased from Macklin, product number: R871932.
[0033] The preparation method of 0.01% D-limonene is as follows: 3 μL D-limonene is dissolved in 27 μL DMSO, and the volume is adjusted to 30 mL with saline to obtain 0.01% D-limonene by volume. The preparation method of 0.02% D-limonene is as follows: 6 μL D-limonene is dissolved in 24 μL DMSO, and the volume is adjusted to 30 mL with saline to obtain 0.02% D-limonene by volume.
[0034] The preparation method of 0.04% D-limonene is as follows: 12 μL of D-limonene is dissolved in 18 μL of DMSO, and the volume is adjusted to 30 mL with physiological saline to obtain 0.04% D-limonene by volume.
[0035] 1. Olfactory Experiment
[0036] 1. Explore the effect of D-limonene on c-fos
[0037] C57 / BL6 mice weighing 20-30 g were randomly divided into a negative control group, a 0.01% D-limonene group, a 0.02% D-limonene group, and a 0.04% D-limonene group, with 3 mice in each group.
[0038] The mice in the negative control group were nebulized to inhale 7.5 mL of normal saline, and the mice in the D-limonene group were nebulized to inhale 7.5 mL of the corresponding concentration of D-limonene. Among them, the effective amount of D-limonene inhaled by the mice in the 0.01% D-limonene group was 0.025-0.0.0375 mL / kg, the effective amount of D-limonene inhaled by the mice in the 0.02% D-limonene group was 0.05-0.075 mL / kg, and the effective amount of D-limonene inhaled by the mice in the 0.04% D-limonene group was 0.1-0.15 mL / kg. After 2 hours, the brains of the mice in each group were perfused and taken out, and then fixed for 6 hours, and then sugar was precipitated for 24 hours, and the frozen sections were kept at a constant temperature with a thickness of 30 μm. After washing, the serum was blocked for 0.5 hours, and then the primary antibody Rbt-a-cfos (1:1000) was used, incubated at room temperature for 2 hours, and incubated at 4°C for 24 hours. After washing with PBS solution for 3 times, incubate with BIO-a-Rbt (1:500) at 4°C overnight, wash with 0.01M PBS solution, incubate with A solution and B solution (ABC KIT; purchased from vectorlabs, item number: PK-6101) mixed for 30 minutes at room temperature for 4 hours, then add 0.03% H2O2 prepared for DAB coloring. After coloring, dehydrate with gradient alcohol and xylene to make it transparent, mount on hanging film, seal with DPX and observe under a light microscope after drying.
[0039] The experimental results are as follows Figure 1 As shown, compared with the negative control group (24.919±7.865), there was no significant difference in the expression of cfos in the piriform cortex of mice that inhaled 0.01% D-limonene (29.72±7.357, p<0.05vs.Saline) compared with the normal saline group, and the expression of c-fos in the piriform cortex of mice that inhaled 0.02% D-limonene (137.868±32.042, p<0.05vs.Saline) and 0.04% D-limonene (141.0±24.635, p<0.05vs.Saline) was significantly increased, but there was no significant statistical difference in the expression of c-fos in the piriform cortex of mice that inhaled 0.02% D-limonene and mice that inhaled 0.04% D-limonene (p>0.05vs.0.02%).
[0040] The above results show that 0.02% volume percentage of D-limonene by aerosol inhalation can activate the piriform cortex. At the same time, the optimal volume percentage of D-limonene is 0.02%. Aerosol inhalation of D-limonene can rapidly activate the piriform cortex in a dose-dependent manner.
[0041] 2. Investigate the effect of D-limonene on the sense of smell of mice
[0042] C57 / BL6 mice weighing 20-30 g were randomly divided into a control group (control) and an experimental group (test).
[0043] On the first day, each group of mice was placed in the middle box of the conditioned place preference experimental device, and the video was recorded for 30 minutes. The time they stayed in the boxes on both sides was measured, and the group that exceeded 150 seconds was discarded. On the second to fifth days, each group of mice was placed in the middle box, and the right box of the conditioned place preference experimental device was sprayed with the corresponding liquid (the experimental group sprayed 7.5mL of 0.02% D-limonene, and the effective amount of D-limonene inhaled by mice was 0.05-0.075mL / kg; the control group sprayed an equal volume of physiological saline), and then the mice were trained for 30 minutes, once in the morning and evening. On the sixth day, each group of mice was placed in the middle box and observed for 30 minutes by video.
[0044] The experimental results are as follows Figure 2 As shown, there was no significant statistical difference in the time the mice stayed in the left and right boxes on the 1st day (Test: 609.52±216.25s vs. Control: 658.47±168.9s, p>0.05) and the 6th day (Test: 310.95±294.9s vs. Control: 214.88±132.44s, p>0.05).
[0045] The above results indicate that D-limonene does not affect the mice's preference or aversion to the odor of D-limonene itself.
[0046] 2. Experimental study on the treatment of pruritus
[0047] 1. To investigate the effect of inhaled D-limonene on acute pruritus
[0048] Six C57 / BL6 mice weighing 20-30 g were injected with 20 μL of saline at the back of the neck, and the video was recorded for 30 minutes to determine the basal threshold. 48 hours after the injection of saline, 20 μL of histamine / chloroquine with a concentration of 10 mg / mL was injected into the back of the neck of the mice, and the video was recorded for 30 minutes. 72 hours after the injection of histamine / chloroquine, 20 μL of histamine / chloroquine with a concentration of 10 mg / mL was injected into the back of the neck of the mice again, and 7.5 mL of 0.02% D-limonene was inhaled by atomization at the same time, and the video was recorded for 30 minutes. 72 hours after inhaling D-limonene, 20 μL of histamine / chloroquine with a concentration of 10 mg / mL was injected into the back of the neck of the mice again, and the video was recorded for 30 minutes. The number of scratches within 30 minutes was counted from the first scratch.
[0049] The experimental results are shown in 3. Figure 3As shown in Figure A, compared with histamine injection at the back of the neck, the number of scratching of mice decreased significantly after aerosol inhalation of D-limonene (His: 94.833±16.546 vs. His+limo: 45.167±25.119, p<0.05); after three days of aerosol inhalation of D-limonene and injection of histamine again, the number of scratching was still significantly lower than the first injection of histamine alone, but there was no significant difference with aerosol inhalation of D-limonene followed by injection of histamine (3d after His+limo vs. His: 59.667±25.583 vs. 94.833±16.546, p<0.05, His+limo vs. 3d after His+limo: 45.167±25.119 vs. 59.667±25.583, p>0.05). Figure 3 As can be seen in Figure B, compared with chloroquine injection at the back of the neck, nebulized inhalation of D-limonene significantly reduced the number of scratching after chloroquine injection (CQ: 163.0±55.606 vs. CQ+limo: 51.667±10.875, p<0.05, N=6). Three days after nebulized inhalation of D-limonene, chloroquine was injected again, and the number of scratching was significantly lower than that of the first injection of chloroquine, but there was no significant difference with chloroquine injection after nebulized inhalation of D-limonene (3d after CQ+limo: 64.5±16.109 vs. CQ: 51.667±10.875 vs. 163.0±55.606, p<0.05, CQ+limo vs. 3d after CQ+limo: 51.667±10.875 vs. 64.5±16.109, p>0.05, N=6).
[0050] The above results show that a single aerosol inhalation of 0.02% D-limonene can quickly relieve histamine itch and chloroquine (non-histamine) itch. After 3 days, the itch behavior was measured again, indicating that the antipruritic effect of D-limonene is still persistent.
[0051] 2. To investigate the effect of inhaled D-limonene on chronic pruritus
[0052] 1) Effect of inhaled D-limonene on atopic dermatitis
[0053] C57 / BL6 mice weighing 20-30 g were randomly divided into a DNFB (2,4-dinitrofluorobenzene) group and a DNFB+limo group, with 4 mice in each group.
[0054] On the first day, the abdominal skin of each group of mice was prepared, and 200 μL of 0.05% DNFB solution was applied. From the 3rd to the 20th day, 150 μL of 0.02% DNFB solution was applied to the back of the neck continuously. On the 17th day, the video recording device was used to record for 30 minutes. Then the mice in the DNFB group inhaled 7.5 mL of normal saline by nebulization, and the mice in the DNFB+limo group inhaled 7.5 mL of 0.02% D-limonene by nebulization, where the effective amount of D-limonene inhaled by mice was 0.05-0.075 mL / kg, and each group of mice was recorded for 30 minutes. After 72 hours of nebulization inhalation of the liquid, the video was recorded again for 30 minutes, and the number of scratches within 30 minutes was counted from the first scratch.
[0055] The experimental results are as follows Figure 4 As shown in middle A, compared with mice with successful atopic dermatitis modeling, the number of scratching in atopic dermatitis model mice decreased after aerosol inhalation of D-limonene (DNFB: 226.00±14.119 vs. DNFB+limo: 85.75±16.681, p<0.05, N=4). Three days after aerosol inhalation of D-limonene, the number of scratching was still lower than the basal value of chronic itch scratching (3d after DNFB+limo: 172.75±15.41 vs. DNFB: 226.00±14.119, p<0.05, N=4).
[0056] The above results show that aerosol inhalation of 0.02% D-limonene by volume has a significant antipruritic effect on atopic dermatitis, and the efficacy lasts for three days.
[0057] 2) Effect of inhaled D-limonene on uremia-related pruritus (CKD)
[0058] C57 / BL6 mice weighing 20-30 g were randomly divided into CKD group and CKD+limo group, with 4 mice in each group.
[0059] Each group of mice was gavaged with 0.5 mL of adenine solution in the morning and evening for 30 days, and the concentration was increased every 5 days, in the order of 0.5 g / mL, 0.75 g / mL, 1.0 g / mL, 1.5 g / mL, 2.0 g / mL and 3.0 g / mL. Video recording was performed for 30 minutes on odd days, and the uremia-related pruritus model was successfully established after the number of scratching exceeded 50 times. Mice in the CKD group inhaled 7.5 mL of saline by nebulization, and mice in the CKD+limo group inhaled 7.5 mL of 0.02% D-limonene by nebulization, wherein the effective amount of D-limonene inhaled by mice was 0.05-0.075 mL / kg. The video recording device was used to record for 30 minutes, and 72 hours after the nebulization of the liquid, the video recording was performed again for 30 minutes, and the number of scratches within 30 minutes was counted from the first scratch.
[0060] The experimental results are as follows Figure 4 As shown in Figure B, compared with before inhalation of D-limonene, the number of scratching times in mice with uremia-related itch model decreased after aerosol inhalation of D-limonene (97.00±35.402 vs. CKD+limo: 22.5±17.407, p<0.05, N=4), and the number of scratching times was lower than the baseline value three days later (p<0.05, N=4), but there was no significant difference compared with after aerosol inhalation of D-limonene (3d after CKD+limo: 27.250±26.133 vs. CKD+limo: 22.500±17.407, p>0.05).
[0061] The above results show that aerosol inhalation of 0.02% D-limonene by volume has a significant antipruritic effect on uremia-related pruritus, and the efficacy lasts for three days.
[0062] 4. To investigate the effect of inhaling D-limonene compared with applying calamine lotion
[0063] C57 / BL6 mice weighing 20-30 g were randomly divided into CQ+limo group and CQ+calamine group, with 6 mice in each group.
[0064] After the neck and back of each group of mice were prepared, 20 μL of 10 mg / mL chloroquine was locally injected, and then the mice in the CQ+limo group immediately inhaled 7.5 mL of 0.02% D-limonene by aerosol, and the effective amount of D-limonene inhaled by mice was 0.05-0.075 mL / kg; 200 μL of calamine lotion (calamine) was applied to the injection area of the neck and back of the mice in the CQ+calamine group. The mice in each group were recorded for 30 minutes using a video measuring device, and the number of scratches within 30 minutes was counted from the first scratch.
[0065] The experimental results are as follows Figure 4 As shown in C, after mice were injected with chloroquine, the number of scratching after applying calamine lotion to the skin was significantly higher than that after aerosol inhalation of D-limonene (CQ+calamine: 122.5±24.720 vs. CQ+limo: 75.833±24.855, p<0.05, N=6).
[0066] The above results show that the antipruritic effect of aerosol inhalation of 0.02% D-limonene by volume is better than that of calamine lotion.
[0067] The above contents are only for explaining the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.
Claims
1. Application of D-limonene in the preparation of drugs for treating pruritus.
2. The use according to claim 1, characterized in that: The pruritus is acute pruritus or chronic pruritus.
3. The use according to claim 2, characterized in that: The acute pruritus is pruritus caused by histamine or non-histamine.
4. The use according to claim 2, characterized in that: The chronic pruritus is the pruritus caused by atopic dermatitis.
5. The use according to claim 2, characterized in that: The chronic pruritus is the pruritus caused by uremia.
6. The use according to any one of claims 1 to 5, characterized in that: The dosage of D-limonene is (0.05-0.15) mL / kg.
7. The use according to any one of claims 1 to 5, characterized in that: The drug is in the form of tablets, capsules, granules, syrups, premixes or pellets for oral administration, or in the form of ointments, injections or sprays for non-oral administration, either alone or mixed with pharmaceutically acceptable excipients or diluents.
8. The use according to claim 7, characterized in that: The spray is a nasal spray.
9. A nasal spray for treating pruritus, characterized in that: Includes D-limonene.
10. A nasal spray for treating pruritus according to claim 9, characterized in that: Includes D-limonene and other remedies for pruritus.
Citation Information
Patent Citations
Nasal spray and preparation method thereof
CN105640932A
Application of limonene in preparation of anti-allergic dermatitis drug
CN111529513A
Antipruritic composition containing terpenoids
JP2019137641A
